The Indian Patent Office has refused to grant US pharmaceutical firm AbbVie a Hepatitis C patent for its combination therapy glecaprevir/pibrentasvir, marketed globally as Mavyret.
Indian pharma firms post strong FY26 revenue growth as major companies across the pharmaceutical and healthcare sectors reported solid sales expansion, strong Q4 recoveries, and improving operational performance.
As India grapples with rising temperatures, the Centre-issued heat advisory recommending AYUSH remedies aims to help citizens stay safe from heat stress and heat-related illnesses.
Calpol has long been a trusted name in Indian households, especially among parents looking for quick fever and pain relief for children. Now, Calpol has received one of the strongest forms of legal recognition in India after the Delhi High Court...
Reporting its fourth quarter results for FY 26, Zydus Wellness, reported a consolidated growth of 62.1% in Net Sales which stood at Rs. 14,761 million as compared to Rs. 9,106 million in the corresponding period of the previous year.
Strides Pharma Science Ltd today announced its consolidated financial results for the quarter (Q4FY26) and Full Year (FY26) ended March 31, 2026. Badree Komandur, MD & Group CEO, commented on the performance and said, “Strides continued to deliver...
India’s pharmaceutical industry is under pressure as rising costs and an export slump squeeze drugmakers hard, impacting profits and slowing growth. Pharmaceutical companies, which have long benefited from strong overseas demand, are now facin...
AI is quietly transforming Indian healthcare. In radiology departments across Mumbai and Bengaluru, AI systems are diagnosing potential tumors in the scans even before the specialist opens the file.
Cancer drug research continues to transform the global pharmaceutical industry as companies race to develop affordable and advanced oncology treatments. New FDA clearances reflect rapid growth in cancer drug research, especially in the breast...
Glenmark Pharmaceuticals announced the launch of its affordable Vancomycin Hydrochloride for Injection USP in the U.S. market in two strengths, 500 mg/vial and 1 g/vial.
.jpg)
.jpg)
, CDSCO.jpg "Fostering a Quality Culture in the Pharmaceutical Industry")